Comparing Outcomes for Patients with HPV Type 16 versus Othe
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is related to improved treatment outcomes. This study finds that no remarkable difference is present between treatment outcomes of OPSCC in HPV 16 type or other high-risk HPV types.

In this study published by the journal Head and Neck Pathology, researchers aimed to evaluate disease control and survival outcomes by HPV DNA genotype.

Patients with primary OPSCC without distant metastases treated with curative intent were retrospectively identified. Patients that underwent HPV DNA polymerase chain reaction (PCR) testing with available genotype were included and dichotomized by the presence of HPV-16 or other high-risk HPV genotypes (HPV-non16). Overall survival (OS), disease-free survival (DFS), locoregional control (LRC), and distant control (DC) were determined.

In our cohort of 193 patients treated with HPV DNA PCR, 10% were detected as HPV-non16 high-risk types.

--Patients with HPV-16 were significantly younger than those with HPV-non16, but no other baseline factors were associated with HPV-non16.

--With a median follow-up of 42.9 months, there were no significant differences in outcomes between the HPV-16 and HPV-non16 groups for 3-year OS, DFS, LRC, or DC.

In conclusion, there is no statistically significant difference in outcomes between OPSCC with HPV-16 and HPV-non16 high-risk genotypes in the cohort, though trends of overall worse survival and disease-free survival in HPV-non 16 OPSCC were seen.

Source: https://doi.org/10.1007/s12105-021-01308-6
Like
Comment
Share